| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | 0.018 | 0.5 |
| mRNA | Topotecan | FIMM | pan-cancer | AAC | 0.068 | 0.5 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.11 | 0.5 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |